647 completed, 224 terminated, 176 recruiting, 82 active not recruiting. 1298 Phase 1, 485 Phase 2.
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prenatal Transplantation for Fetuses With Fanconi Anemia IUHSCT for FA-affected fetuses - Fanconi Anemia, Anemia, Hypoplastic, Congenital | Phase 1 / Phase 2 | Not yet recruiting | Agnieszka Czechowicz | 12 | 2028-01-01 | 2026-06-16 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) Allogeneic umbilical cord mesenchymal stem cells, Decitabine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-17 | 2026-11-12 |
| Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders Filgrastim, Plerixafor, Leukapheresis - Bone Marrow Failure Syndrome | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 12 | 2026-11-01 | 2026-10-06 |
| Allogeneic iNKT Cell Therapy (agenT-797) After SCT agenT-797 - Allogenic Stem Cell Transplantation, Myeloid Malignancies | Phase 1 | Recruiting | University of Wisconsin, Madison | 22 | 2026-11-01 | 2026-11-12 |
| Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS Ziftomenib - Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | Phase 1 | Not yet recruiting | Kura Oncology, Inc. | 126 | 2026-10-30 | 2026-11-10 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| Prophylactic DLI-X for Leukemia Relapse After HCT Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI - Acute Lymphoid Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | University of Arizona | 180 | 2026-10-26 | 2026-10-29 |
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-10-26 | 2026-11-12 |
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia Metformin, Naproxen Sodium - Fanconi Anemia, Head and Neck Cancer | Phase 1 | Recruiting | Rockefeller University | 80 | 2026-10-14 | 2026-10-28 |
| Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT Anakinra - Poor Graft Function, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 66 | 2026-10-05 | 2026-10-22 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML CD64 CAR T Cells - Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML) | Phase 1 | Recruiting | University of Colorado, Denver | 23 | 2026-09-10 | 2026-10-20 |
Showing 20 of 1298. Sign in to see all of them.
Myelodysplastic Syndromes (703) · Leukemia, Myeloid, Acute (644) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (327) · Leukemia (289) · Leukemia, Myelomonocytic, Chronic (232) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (231) · Primary Myelofibrosis (199) · Myeloproliferative Disorders (181) · Lymphoma, Non-Hodgkin (151) · Blast Crisis (148) · Leukemia, Lymphocytic, Chronic, B-Cell (146) · Multiple Myeloma (143) · Hodgkin Disease (125) · Congenital Abnormalities (112) · Lymphoma (112)
Hemic and Lymphatic Diseases (1298) · Hematologic Diseases (1273) · Neoplasms (954) · Neoplasms by Histologic Type (945) · Leukemia, Myeloid (861) · Leukemia (639) · Pathologic Processes (604) · Pathological Conditions, Signs and Symptoms (604) · Disease Attributes (594) · Chronic Disease (555) · Immune System Diseases (451) · Myeloproliferative Disorders (435) · Immunoproliferative Disorders (432) · Lymphatic Diseases (424)
Azacitidine (136) · Cytarabine (95) · Cyclophosphamide (91) · fludarabine phosphate (86) · fludarabine (81) · Decitabine (60) · ruxolitinib (58) · Filgrastim (56) · venetoclax (54) · Mycophenolic Acid (47) · Whole-Body Irradiation (47) · Peripheral Blood Stem Cell Transplantation (44) · Tacrolimus (43) · Busulfan (39) · Cyclosporine (39)
M.D. Anderson Cancer Center (88) · National Cancer Institute (NCI) (82) · Fred Hutchinson Cancer Center (40) · Novartis Pharmaceuticals (31) · City of Hope Medical Center (25) · National Heart, Lung, and Blood Institute (NHLBI) (20) · Washington University School of Medicine (20) · Masonic Cancer Center, University of Minnesota (19) · Memorial Sloan Kettering Cancer Center (19) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (16) · Incyte Corporation (16) · Bristol-Myers Squibb (14) · Dana-Farber Cancer Institute (13) · Celgene (11)
United States (964) · France (96) · China (94) · Germany (86) · Canada (77) · Italy (77) · United Kingdom (73) · Australia (67) · Spain (67) · Japan (44) · South Korea (44) · Netherlands (30) · Belgium (28) · Poland (19) · Singapore (19)
Jorge Cortes, MD (11) · Ronald Hoffman, MD (7) · Brenda Sandmaier (6) · Guillermo Garcia-Manero, MD (6) · John Mascarenhas, MD (6) · Ayalew Tefferi, MD (5) · Farhad Ravandi-Kashani, MD (5) · Gautam Borthakur, MD (5)
PMID 42013378, PMID 27400247, PMID 32499241, PMID 16775234, PMID 25310303, PMID 25824692, PMID 31527168, PMID 34699069, PMID 34724566, PMID 11331327, PMID 11585760, PMID 12114413, PMID 12171484, PMID 12750167, PMID 15231574, PMID 15514371, PMID 15570084, PMID 15958631, PMID 16275934, PMID 16278404, PMID 16609072, PMID 16670265, PMID 16775235, PMID 16882711, PMID 16990776, PMID 17151364, PMID 17562873, PMID 17640728, PMID 17715389, PMID 17875804, PMID 17959855, PMID 17971589, PMID 18048643, PMID 18172005, PMID 18299450, PMID 18327587, PMID 18467731, PMID 18571721, PMID 18974373, PMID 19010875, PMID 19029442, PMID 19075272, PMID 19092853, PMID 19109557, PMID 19139736, PMID 19179301, PMID 19398716, PMID 19439093, PMID 19503090, PMID 19546476
P30CA033572 (19), P30CA015704 (16), P30CA006973 (15), 2023 (14), P30CA016672 (11), U01CA070095 (11), U01CA062461 (10), 2016 (8), 2018 (8), 2025 (6), U01CA097452 (6), 2014 (5), 2015 (5), 2017 (5), 2019 (5)